Call for more transparency in manufacturers declarations on serum indices: On behalf of the Working Group for Preanalytical Phase (WG-PRE), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 484, 328-332
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A pragmatic approach to sample acceptance and rejectionClinical Biochemistry, 2017
- Harmonization of automated hemolysis index assessment and use: Is it possible?Clinica Chimica Acta, 2014
- Reference range of hemolysis index in serum and lithium-heparin plasma measured with two analytical platforms in a population of unselected outpatientsClinica Chimica Acta, 2014
- Heterogeneity of manufacturers' declarations for lipemia interference — An urgent call for standardizationClinica Chimica Acta, 2013
- Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assaysClinica Chimica Acta, 2011
- Evaluation of bilirubin concentration in hemolysed samples, is it really impossible? The altitude-curve cartography approach to interfered assaysClinica Chimica Acta, 2011
- Hemolysis detection and management of hemolysed specimensBiochemia Medica, 2010
- Interference of Blood Cell Lysis on Routine Coagulation TestingArchives of Pathology & Laboratory Medicine, 2006
- Why is the laboratory an afterthought for managed care organizations?Clinical Chemistry, 1996
- Erroneous laboratory results from hemolyzed, icteric, and lipemic specimensClinical Chemistry, 1993